DOYLESTOWN, Pa.--(BUSINESS WIRE)--QuantRx Biomedical Corporation, (OTCBB:QTXB.OB), a broad-based diagnostics company focused on the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide healthcare industry, today announced that its molecular imaging group, FluoroPharma, Inc., a company developing breakthrough cardiovascular molecular imaging agents for the PET market, has entered into a license agreement with Massachusetts General Hospital (MGH) for the development and commercialization of agents for diagnosis and treatment of Alzheimer’s disease (AD). The licensed technologies, which were co-developed by FluoroPharma and MGH scientists, target multiple biological processes associated with Alzheimer’s disease. Currently, there is no single diagnostic test that proves a person has Alzheimer’s. Development of new options for early detection and treatment of Alzheimer’s has the potential to improve patient care and create new paths for AD management for the more than 5 million Americans that suffer from dementia and other cognitive deficits as a result of AD.
